Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Market Outlook

Thelansis’s “Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Metastatic Castration-Resistant Prostate Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Overview

Non-metastatic castration-resistant prostate cancer (nmCRPC), or M0 CRPC, is a transitional stage in which patients exhibit resistance to castration (testosterone levels drop below 50 ng/mL) after undergoing ADT. At this stage, no visible metastases appear on standard imaging exams, PSA levels continue to rise, reaching a minimum increase of 25% from their lowest point (starting with a PSA level of at least 1.0 ng/mL) and a minimum rise of 2 ng/mL, with confirmation required from a second measurement. PSA progression can happen before the detection of metastases, either due to local recurrence in the prostate bed after prostatectomy or persistent local disease following radical radiation therapy, or in cases where no disease is detected at the primary site, no involved lymph nodes are found in computed tomography (CT) or magnetic resonance imaging (MRI) (lymph nodes smaller than 1.5 cm in the pelvis are not considered). No disease is observed in bones or visceral organs. Most nonmetastatic castration-resistant prostate cancer patients eventually develop metastatic lesions, leading to morbidity and mortality of prostate cancer. Next-generation imaging (NGI) techniques have improved diagnostic accuracy and capabilities. Modalities such as whole-body diffusion-weighted MRI and positron emission tomography (PET) using targeted radiotracers like prostate-specific membrane antigen (PSMA) PET, NaF PET, 11C-choline, and 18F-fluciclovine PET/CT have significantly enhanced the ability to detect metastases. The U.S. Food and Drug Administration (FDA) has approved the use of two androgen receptor antagonists, enzalutamide and apalutamide, as treatments for nonmetastatic castration-resistant prostate cancer.

• Non-metastatic castration-resistant prostate cancer (nmCRPC) affects approximately 50,000 to 60,000 individuals annually in the United States, constituting 7% to 12% of men with prostate cancer who receive androgen therapy.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: